XML 23 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Operating activities:      
Net income (loss) $ 52,549 $ (190,284) $ (76,613)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:      
Stock-based compensation 66,406 49,086 46,553
Asset impairments and write-downs 0 1,000 840
Depreciation and amortization 14,194 14,386 11,595
Amortization of right-of-use assets 5,563 5,438 4,412
Unrealized loss on long-term marketable equity securities 0 0 1,181
Realized gain on sale of long-term marketable equity securities, net 0 (284) 0
Loss on disposal of asset 91 44 0
Gain on settlement of obligation and recovery of written-off investment 0 (2,109) 0
Revaluation of common stock warrant liability to estimated fair value 0 (10) (107)
Revaluation of contingent consideration to estimated fair value 931 2,677 727
Amortization of premium and accretion of discount on short-term marketable securities, net 621 (4,927) 390
Changes in operating assets and liabilities:      
Accounts receivable (13,741) 16,016 (6,660)
Inventory (1,018) 54 (2,859)
Prepaid and other assets 606 1,767 (1,049)
Accounts payable (5,110) 2,904 (2,054)
Accrued compensation 18,667 2,655 (9,251)
Accrued and other liabilities (95,661) 89,608 11,327
Accrued royalties 0 (1,557) 0
Operating lease liabilities, net (5,863) (5,418) (3,456)
Change in deferred taxes (187) 566 (215)
Net cash provided by (used in) operating activities 38,048 (18,388) (25,239)
Investing activities:      
Maturities of short-term marketable securities 166,921 256,038 111,587
Purchases of short-term marketable securities (160,286) (201,165) (315,145)
Purchase of corporate equity securities (634) (965) 0
Proceeds from sale of equity securities 0 2,460 0
Additions of capital expenditures (6,484) (8,344) (21,234)
Acquisition of intangible assets 0 (896) (3,100)
Acquisition of business, net of cash acquired 0 (6,682) (610)
Net cash (used in) provided by investing activities (483) 40,446 (228,502)
Financing activities:      
Payment of contingent consideration (5,325) (625) (2,625)
Repurchase and retirement of common stock (522) (27,541) (642)
Proceeds from exercise of warrants 0 4 0
Proceeds from exercise of stock options 8,936 120 2,435
Proceeds from issuance of common stock under employee stock purchase plan 1,397 1,495 2,230
Taxes paid related to net share settlement of restricted stock units (10,092) (3,059) (5,933)
Net cash used in financing activities (5,606) (29,606) (4,535)
Effect of exchange rate changes on cash and cash equivalents 532 (112) 23
Net increase (decrease) in cash, cash equivalents and restricted cash 32,491 (7,660) (258,253)
Cash, cash equivalents, and restricted cash at beginning of period 82,783 90,443 348,696
Cash, cash equivalents, and restricted cash at end of period 115,274 82,783 90,443
Supplemental disclosures of cash information      
Cash paid for interest 0 0 8
Cash paid for income taxes 317 738 392
Supplemental disclosures of cash flow information      
Shares issued in lieu of payment 174 216 319
Operating lease right-of-use assets 195 607 22,267
Purchases of capital expenditures in accounts payable and accrued liabilities 633 647 1,423
Employee stock purchase plan shares included in accrued compensation 975 556 686
Contingent consideration $ 0 $ 3,499 $ 0